Global Patent Index - EP 2658579 A4

EP 2658579 A4 20150722 - IN VIVO POLYNUCLEOTIDE DELIVERY CONJUGATES HAVING ENZYME SENSITIVE LINKAGES

Title (en)

IN VIVO POLYNUCLEOTIDE DELIVERY CONJUGATES HAVING ENZYME SENSITIVE LINKAGES

Title (de)

KONJUGATE ZUR IN-VIVO-ABGABE VON POLYNUKLEOTIDEN MIT ENZYMEMPFINDLICHEN BINDUNGEN

Title (fr)

CONJUGUÉS D'ADMINISTRATION DE POLYNUCLÉOTIDE IN VIVO AYANT DES LIAISONS SENSIBLES À DES ENZYMES

Publication

EP 2658579 A4 20150722 (EN)

Application

EP 11853858 A 20111228

Priority

  • US 201113336028 A 20111223
  • US 201061427936 P 20101229
  • US 2011067588 W 20111228

Abstract (en)

[origin: WO2012092373A2] The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active poiyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalentiy linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.

IPC 8 full level

A61K 48/00 (2006.01); A61K 47/48 (2006.01); C07C 69/96 (2006.01); C08G 63/91 (2006.01)

CPC (source: EP KR RU)

A61K 47/58 (2017.08 - EP); A61K 47/60 (2017.08 - EP); A61K 48/00 (2013.01 - KR); A61P 1/16 (2018.01 - EP); A61P 35/00 (2018.01 - EP); C07C 69/96 (2013.01 - KR); C07C 233/05 (2013.01 - KR); C07K 5/06034 (2013.01 - EP); C07K 5/06078 (2013.01 - EP); C07K 5/06104 (2013.01 - EP); C07K 5/06113 (2013.01 - EP); C08G 63/91 (2013.01 - KR); C12N 15/87 (2013.01 - EP); C07K 5/06034 (2013.01 - RU); C07K 5/06078 (2013.01 - RU); C12N 15/111 (2013.01 - EP); C12N 2310/14 (2013.01 - EP); C12N 2310/3513 (2013.01 - EP); C12N 2320/32 (2013.01 - EP); C12N 2800/95 (2013.01 - EP); C12N 2810/10 (2013.01 - EP)

Citation (search report)

Citation (examination)

  • KUMAR S K ET AL: "Modulating paclitaxel bioavailability for targeting prostate cancer", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 14, 15 July 2007 (2007-07-15), pages 4973 - 4984, XP026265762, ISSN: 0968-0896, [retrieved on 20070715], DOI: 10.1016/J.BMC.2007.04.029
  • YONEDA Y ET AL: "A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 5, 1 March 2008 (2008-03-01), pages 1632 - 1636, XP022683109, ISSN: 0960-894X, [retrieved on 20080119], DOI: 10.1016/J.BMCL.2008.01.060

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2012092373 A2 20120705; WO 2012092373 A3 20131024; AU 2011352204 A1 20130502; AU 2011352204 B2 20150521; BR 112013014115 A2 20190924; CA 2816041 A1 20120705; CA 2816041 C 20190108; CL 2013001876 A1 20140411; CL 2015003580 A1 20160715; CN 103491982 A 20140101; CN 103491982 B 20170912; EP 2658579 A2 20131106; EP 2658579 A4 20150722; JP 2014505685 A 20140306; JP 5941926 B2 20160629; KR 20130136494 A 20131212; MX 2013007316 A 20130729; MX 341118 B 20160809; MX 347298 B 20170421; NZ 611656 A 20141031; PE 20140198 A1 20140221; RU 2013117286 A 20150310; RU 2619453 C2 20170516; SG 189942 A1 20130628; ZA 201302896 B 20140725

DOCDB simple family (application)

US 2011067588 W 20111228; AU 2011352204 A 20111228; BR 112013014115 A 20111228; CA 2816041 A 20111228; CL 2013001876 A 20130625; CL 2015003580 A 20151210; CN 201180061179 A 20111228; EP 11853858 A 20111228; JP 2013547648 A 20111228; KR 20137017195 A 20111228; MX 2013007316 A 20111228; MX 2016006733 A 20111228; NZ 61165611 A 20111228; PE 2013001496 A 20111228; RU 2013117286 A 20111228; SG 2013029830 A 20111228; ZA 201302896 A 20130422